MDTQueued from the May 25, 2026 S&P 500 market-cap snapshot ranks 101-125; market capitalization was rechecked against CompaniesMarketCap during the May 27, 2026 registry refresh.

Medtronic

Medtronic develops and sells medical devices for cardiovascular, neuroscience, diabetes, and surgical care.

CompaniesMarketCap Product analyses

Metadata

Where this company sits

Ticker: MDT
Rank snapshot: ≈ 112
Sector: Health Care
Industry: Pharma & MedTech
Region: United States
Index: S&P 500 · Top 125 by market cap

Metrics

Scoring view

Every metric is paired with a short rationale. The numbers are deliberate, not divine.

Moat

82.0/10

Regulated medical devices, clinical evidence requirements, physician and hospital relationships, patient support obligations, and manufacturing quality systems create strong barriers, especially in implantable cardiovascular and neuroscience products.

Decentralizability

31.0/10

Software, data interfaces, diabetes control algorithms, documentation, and some external-device hardware can be opened, but implantable and life-sustaining devices remain constrained by clinical validation, sterile manufacturing, regulation, and liability.

Profitability

69.0/10

Medtronic remains a large profitable medtech company with diversified device portfolios, though growth and margins vary across segments and are affected by R&D, regulatory, and supply-chain costs.

Price / Earnings

26.0x

Recent market-data pages showed Medtronic trading near a $100 billion market capitalization; the P/E estimate is a directional public-market input rather than a normalized valuation judgment.

Market cap

$100.3B

CompaniesMarketCap listed Medtronic at approximately $100.33 billion in market capitalization as of May 2026.

Freed-up capital potential

$0.0

Derived from market cap, moat resistance, decentralizability, and profitability. It is a directional estimate of value capture that could come under pressure if open alternatives compound.

Narrative

Why the company matters

A short editorial overview plus the current thesis on moat strength and decentralization pressure.

Business mix

Medtronic reports through Cardiovascular, Neuroscience, Medical Surgical, and Diabetes segments, with products spanning cardiac rhythm management, vascular intervention, neurostimulation, spine and brain therapies, surgical tools, respiratory and gastrointestinal care, insulin pumps, continuous glucose monitoring, and smart insulin pens.

Its most visible device franchises are high-compliance clinical products sold into physician, hospital, and chronic-care workflows where safety evidence, reimbursement, service infrastructure, and regulatory approvals matter as much as hardware design.

Refresh posture

This refresh treats Medtronic as a durable medtech incumbent rather than a software platform. Its strongest moat is not a single closed ecosystem, but the combined effect of regulated implants, clinical evidence, distribution, physician familiarity, and patient support obligations.

The most credible open or decentralized pressure appears first in diabetes automation, where patient-led open-source artificial pancreas projects already document interoperable control logic around existing devices. Implantable cardiac hardware is less decentralizable today because manufacturing quality, sterile supply chains, clinical trials, and post-market surveillance remain hard constraints.

Moat reading

Medtronic has a high moat because many of its products are invasive or life-sustaining medical devices with FDA or equivalent regulatory pathways, physician training requirements, hospital procurement relationships, long service lives, and substantial clinical evidence expectations. These factors protect the business even when the underlying electronics are not exotic.

The moat is weaker in non-implantable connected-care categories such as diabetes automation, where open-source communities have shown that algorithmic dosing support, interoperability, and patient agency can advance outside traditional vendor release cycles. Even there, commercial reliability, liability, supplies, support, and reimbursement preserve a meaningful incumbent advantage.

Decentralization reading

Medtronic is only moderately decentralizable overall. Some control software, data review, closed-loop logic, training material, and noncritical peripherals can move toward open protocols, patient-owned data, and community audit. That does not make the regulated device stack itself easy to decentralize.

The best near-term decentralization thesis is modularity: open algorithms, open data interfaces, transparent safety constraints, local repair where legally permitted, and community-run evidence registries that pressure proprietary ecosystems. Fully decentralized implant manufacturing or unsupervised DIY therapy would be irresponsible without validated quality systems and clinical oversight.

Products

Where the moat actually touches users

These pages zoom into the products and services that matter most to each company, the alternatives already nibbling at them, and 3 structured disruption concepts across the current product set.

3 disruption concepts tracked0 documented exceptions

MiniMed

Diabetes insulin pump and automated insulin delivery system

2 concepts

MiniMed is Medtronic's insulin pump and automated insulin delivery franchise, including the MiniMed 780G system for closed-loop diabetes management.

Open analysis

Micra

Leadless pacemaker

1 concept

Micra is Medtronic's leadless pacemaker family, implanted directly in the heart rather than using a chest pocket and transvenous leads.

Open analysis

Technology waves

Strategic lenses

These are the repo's explicit bias terms: the technologies expected to keep making incumbents less inevitable over time.

Printed electronics and PCB tooling

PCB fabrication, chip packaging, and increasingly automated electronics assembly continue shrinking the distance between prototype and local production.

• Incumbents with hardware lock-in should be evaluated against a future of much cheaper custom electronics.
• Pick-and-place automation lowers the coordination cost for distributed manufacturing cells.
• The most durable hardware moats may migrate toward fabs, ecosystems, and compliance rather than assembly itself.

Microfactories and automated mini-home production

Small, software-defined manufacturing cells could make localized production less eccentric and more default.

• Products with heavy branding but generic bill-of-materials profiles look increasingly vulnerable.
• Logistics moats still matter, but their margin for arrogance should narrow.
• Open-source production recipes can pressure both price and product differentiation.

Paper trail